Resmetirom is the active ingredient in Madrigal Pharmaceuticals' Rezdiffra, a once-daily oral thyroid hormone receptor-beta selective agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) in March 2024. The drug exploits THR-β's liver-selective expression to drive hepatic fat oxidation while sparing the cardiac and skeletal-muscle THR-α effects that doomed earlier thyromimetic candidates.
The approval rested on histologic endpoints from the Phase 3 MAESTRO-NASH trial: MASH resolution without fibrosis worsening and at least one-stage fibrosis improvement at week 52, with the 80 mg and 100 mg arms both beating placebo. Through 2025 and into 2026, the data package has widened to cardiovascular markers and portal-hypertension risk in F4c MASH cirrhosis (ANTICIPATE-NASH at EASL 2026), and resmetirom has become the comparator and combination partner of choice as GLP-1, glucagon-dual, and FASN-inhibitor MASH candidates read out.
Stories here cover resmetirom's trial readouts, label work, and the MASH combination landscape. See #rezdiffra, #madrigal-pharmaceuticals, and #thr-beta for adjacent threads.
Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). HRS-4729's specific molecular mechanism has not been publicly disclosed in detail; the MAFLD/hepatitis indication placement suggests likely mechanisms include FGF21 analog, thyroid hormone receptor beta agonist, or a novel liver-target mechanism. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist licensed ex-China to Kailera Therapeutics for global Phase 3 initiation in H1 2027) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.
Madrigal Pharmaceuticals delivered eight Rezdiffra (resmetirom) poster presentations at EASL 2026 today. Key data: secondary analysis of MAESTRO-NASH and MAESTRO-NAFLD-1 documented Rezdiffra-driven improvements in cardiovascular lipid risk markers (Lp(a), LDL-C, ApoB); a two-year analysis in patients with compensated MASH cirrhosis (F4c) showed meaningful improvement in ANTICIPATE-NASH risk scores, a validated marker for clinically significant portal hypertension. Real-world effectiveness analyses and noninvasive biomarker plus machine-learning models for predicting MASH and fibrosis improvement rounded out the presentation slate. Rezdiffra (resmetirom) — a thyroid hormone receptor β agonist small molecule, not a peptide — was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The compensated MASH cirrhosis (F4c) data extend the case toward an indication where the GLP-1/glucagon peptide programs (pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) are also competing.
Sagimet Biosciences presented two posters at EASL 2026 today on the combination of its denifanstat (FASN inhibitor small molecule) with Madrigal's Rezdiffra (resmetirom, thyroid hormone receptor β agonist) for MASH. The combination work tests whether layered MASH therapies producing complementary mechanism-of-action effects can outperform either monotherapy. Denifanstat inhibits fatty acid synthase — the enzyme producing the majority of newly synthesized fatty acids in the liver — reducing hepatic lipogenesis upstream of the inflammation and fibrosis cascade that resmetirom addresses through downstream thyroid-hormone-receptor mechanisms. The combination represents the broader trend of MASH-as-multi-mechanism-battleground that defines EASL 2026: GLP-1/glucagon peptides (pemvidutide, DA-1726, survodutide), RNAi (ARO-INHBE), thyroid hormone agonism (Rezdiffra), FASN inhibition (denifanstat), and galectin-3 inhibition (belapectin) all running parallel programs.
Madrigal Pharmaceuticals announced May 20 that multiple abstracts from its Rezdiffra (resmetirom) development and real-world evidence programs will be presented at EASL 2026 in Barcelona. Headline analyses include cardiovascular risk markers — secondary analysis of Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 examining improvements in Lp(a), LDL-C, and ApoB — and portal hypertension risk improvement in compensated MASH cirrhosis (F4c) measured by ANTICIPATE-NASH risk scores. Real-world evidence and noninvasive biomarker analyses round out the slate. Rezdiffra (a thyroid hormone receptor β agonist, not a peptide) was approved March 2024 as the first FDA-approved MASH therapy for noncirrhotic MASH with F2-F3 fibrosis. The EASL data extend the case toward compensated MASH cirrhosis and cardiovascular outcomes — a competitive context for the GLP-1/glucagon peptide programs (semaglutide ESSENCE, pemvidutide IMPACT, survodutide SYNCHRONIZE-1, retatrutide MASLD Phase 3) running on parallel tracks.